SCHEMBL14130698

SCHEMBL14130698

Cc1ccc(OC(=O)c2ccco2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 16/20 0.72
SMN1; SMN2 Q16637 4/20 0.72
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
TP53 P04637 1/20 0.72
RECQL P46063 1/20 0.72
PKM P14618 2/20 0.62
MAPT P10636 4/20 0.61
KDM4E B2RXH2 2/20 0.61
MEN1 O00255 2/20 0.61
NPSR1 Q6W5P4 1/20 0.61
ALDH1A1 P00352 6/20 0.61
HSD17B10 Q99714 3/20 0.61
TSHR P16473 3/20 0.57
GAA P10253 2/20 0.57
HPGD P15428 2/20 0.57
HTT P42858 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
LMNA P02545 1/20 0.57
ALOX15 P16050 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13381577 0.91 KMT2A (0.75) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL5943067 0.83 KMT2A (0.76) KMT2ASMN1; SMN2NPC1RAB9APKM
SCHEMBL25054068 0.83 KMT2A (0.74) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL13802894 0.82 KMT2A (0.64) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL9047691 0.82 KMT2A (0.64) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL12591803 0.81 KMT2A (0.63) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL16797441 0.81 RAB9A (0.65) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL13791553 0.81 KMT2A (0.85) KMT2ASMN1; SMN2RECQLPKMMAPT
SCHEMBL6382860 0.81 KMT2A (0.71) KMT2ASMN1; SMN2NPC1RAB9ATP53
SCHEMBL25054116 0.79 KMT2A (0.60) KMT2ASMN1; SMN2NPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102946882-B Phenylalamine derivatives and as the purposes of non-peptide GLP-1-1 receptor modulators ARGUSINA, INC. (US) 2016-05-18 CN disclosed
CN-102946882-A Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators ARGUSINA INC 2013-02-27 CN disclosed
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2008-07-31 US disclosed
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2008-07-31 US disclosed
WO-2008062276-A2 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS SCD, SCD5, ACACA KMT2A 2996/4885SMN1; SMN2 2065/4885NPC1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.